SecBot

SecBot
Nasdaq· Pharmaceutical Preparations· Inc. DE· CIK 0001818794

DYN

Dyne Therapeutics, Inc.
$15.20 ▼ -3.92%
Prev close $15.82
Market cap$3.0B
ConsensusStrong Buy
12-mo target$36.00 (+136.8%)
▲ Bullish
Analyst conviction 9/10
Insider Selling Cluster (4 insiders)High Impact Filing (7/10)19 New Institutional Positions13 Institutional Exits Biotech & Drug Discovery
Snapshot
The big-picture read on DYN right now — valuation, ownership and activity at a glance.
Market Cap
$3.0B
Cap Size
Mid Cap
Analyst Consensus
Strong Buy (90%)
Inst. Holders
50 funds
Inst. Value
$2.1B
Inst. Activity
19 buys / 13 sells
Insider Activity
$0.00 buy / $113.8M sell
Insider Net $
-$113.8M
SEC Reports
20
Press Releases
6
Price chart 30d -39.1%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Jan 21, 2027 fda_pdufa
PDUFA: DYN — z-rostudirsen in Duchenne muscular dystrophy amenable to exon 51 skipping — 2027-01-21
FDA target action date 2027-01-21 for DYN (Dyne Therapeutics, Inc.). Drug: z-rostudirsen. Indication
Sep 8, 2026 Insider
Cox John sold 5,658 shares
CEO & President @ $18.88 ($106.8K)
Sep 8, 2026 Insider
Kerr Douglas sold 1,290 shares
Chief Medical Officer @ $18.88 ($24.4K)
Sep 8, 2026 Insider
Friedl-Naderer Johanna sold 185 shares
Chief Commercial Officer @ $18.88 ($3.5K)
Aug 18, 2026 SEC
Director Jason P. Rhodes sold ~$65.2M worth of DYN shares (1.4% of market cap) in a cluster over two days, while CEO Joh
CLUSTER — Impact 6/10
Aug 14, 2026 SEC
Atlas Venture, a founding investor in Dyne Therapeutics, filed multiple Form 144 notices on August 14, 2026, signaling i
144 — Impact 4/10
Aug 13, 2026 SEC
Director Douglas Kerr filed a Form 144 notice of intent to sell 2,443 shares of Dyne Therapeutics common stock, with an
144 — Impact 2/10
Jul 22, 2026 Press
Dyne Therapeutics priced an upsized underwritten public offering of 18.3 million shares at $20.50 per share, raising gro
Impact 6/10
Analyst ratings buy % +5.9%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
Strong Buy 90% rate it Buy or better · 21 analysts
Strong Buy 7 33% Buy 12 57% Hold 2 10% Sell 0 0% Strong Sell 0 0%
Recent analyst actions
DateFirmActionRatingFirm rating
Sep 30, 2026Chardan CapitalMAINTAINBuy 49%
Sep 30, 2026HC Wainwright & Co.MAINTAINBuy 43%
Sep 29, 2026Piper SandlerREITERATEOverweight 54%
Sep 9, 2026Morgan StanleyMAINTAINOverweight 55%
Sep 9, 2026JP MorganDOWNGRADEUnderweight 55%
Sep 9, 2026RBC CapitalMAINTAINOutperform 55%
Sep 9, 2026BairdMAINTAINOutperform 54%
Jul 31, 2026Morgan StanleyMAINTAINOverweight 55%
Jul 30, 2026RBC CapitalMAINTAINOutperform 55%
Jul 23, 2026Cantor FitzgeraldINITIATEOverweight 49%
Monthly consensus history
PeriodStr. BuyBuyHoldSellStr. SellBuy %Distribution
Sep 1, 202671220090%
Aug 1, 202671220090%
Jul 1, 202671130086%
Jun 1, 202671030085%
May 1, 202671030085%
Apr 1, 202671030085%
Mar 1, 202671030085%
Feb 1, 202671030085%
Price targets
Where 15 covering analysts think DYN trades over the next 12 months.
$36.00 +136.8% upside Strong Buy
Current$15.20 Low$10.00 Median$37.00 High$50.00 15 analysts
$10.00$50.00
Analyst rating Strong Buy· 1.4/5 as of Oct 2, 2026
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
20 SEC filing reports analyzed · 3 bullish, 3 bearish, 1 mixed, 13 neutral · avg impact 3.9/10.Plus 6 press releases.
BEARISHCLUSTER6/10
Director Jason P. Rhodes sold ~$65.2M worth of DYN shares (1.4% of market cap) in a cluster over two
Aug 18, 2026
NEUTRAL1444/10
Atlas Venture, a founding investor in Dyne Therapeutics, filed multiple Form 144 notices on August 1
Aug 14, 2026
NEUTRAL1442/10
Director Douglas Kerr filed a Form 144 notice of intent to sell 2,443 shares of Dyne Therapeutics co
Aug 13, 2026
NEUTRAL1442/10
Erick Lucera, an officer of Dyne Therapeutics, filed a Form 144 on August 13, 2026, indicating inten
Aug 13, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Jan 21, 2027
fda_pdufa
PDUFA: DYN — z-rostudirsen in Duchenne muscular dystrophy amenable to exon 51 skipping — 2027-01-21
FDA target action date 2027-01-21 for DYN (Dyne Therapeutics, Inc.). Drug: z-rostudirsen. Indication: Duchenne muscular dystrophy amenable to exon 51
Sep 30, 2026
short_volume
Short Volume: DYN — 64.9% short (1.1M / 1.7M)
Short: 1,083,413 | Exempt: 465 | TRF Vol: 1,669,938 | Short Ratio: 64.9% | Off-exchange volume (dark pool + OTC)
Sep 29, 2026
fda
Dyne Therapeutics Announces Additional One-Year Clinical Data from Phase 1/2 ACHIEVE Trial of Z-Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 (DM1)
- Data from a pooled dose group of participants initially enrolled in the multiple ascending dose (MAD) portion of ACHIEVE showed functional improveme
Sep 29, 2026
short_volume
Short Volume: DYN — 56.0% short (0.5M / 0.8M)
Short: 457,386 | Exempt: 6,801 | TRF Vol: 816,831 | Short Ratio: 56.0% | Off-exchange volume (dark pool + OTC)
Sep 28, 2026
short_volume
Short Volume: DYN — 62.4% short (0.6M / 1.0M)
Short: 606,560 | Exempt: 0 | TRF Vol: 971,695 | Short Ratio: 62.4% | Off-exchange volume (dark pool + OTC)
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
PeriodEPS Est.RangeGrowth30d RevUp/DnRevenue#
Current Q$-0.89$-1.09–$-0.72-16.8%-1.0%1↑ 9↓$0.0B14
Next Q$-0.89$-1.11–$-0.36-22.2%-1.2%2↑ 8↓$0.0B14
Current FY$-3.55$-3.94–$-2.94-2.3%+0.6%0↑ 11↓$0.0B15
Next FY$-3.34$-4.53–$-2.796.0%+0.1%2↑ 8↓$0.1B13
Current-quarter EPS estimate — revision history
WhenEPS estimateChange vs now
Current$-0.888—
7d ago$-0.888—
30d ago$-0.878-0.009
60d ago$-0.858-0.030
90d ago$-0.765-0.122
Institutional ownership
Which big funds own DYN (from quarterly 13F filings) and who is adding or trimming.
50 institutional holders with $2.1B total value (96,312,379 shares) as of 2026-Q2. Top holders: BlackRock,, Jupiter, FMR. Net buying activity: 19 institutions added/increased vs 13 reduced.
Top holders — 2026-Q2
FundSharesValue% TrackedLast move
BlackRock, Inc.12,404,330$275.5M12.9%—
Jupiter Topco LLC11,997,738$266.6M12.5%—
FMR LLC11,207,000$248.9M11.7%ADD +25.8%
STATE STREET CORP7,458,263$165.6M7.8%—
Orbis Allan Gray Ltd7,006,542$155.6M7.3%ADD +40.8%
VANGUARD CAPITAL MANAGEMENT LLC6,310,969$140.2M6.6%—
VANGUARD PORTFOLIO MANAGEMENT LLC4,048,428$89.9M4.2%—
GEODE CAPITAL MANAGEMENT, LLC3,743,427$83.2M3.9%—
JPMORGAN CHASE & CO3,151,656$67.2M3.1%—
BANK OF AMERICA CORP /DE/2,233,398$49.6M2.3%ADD +54.7%
Recent position changes
FundActionPrevCurrentChangeValue
FMR LLCADD8,908,98011,207,000+25.8%$248.9M
BANK OF AMERICA CORP /DE/ADD1,443,3132,233,398+54.7%$49.6M
GOLDMAN SACHS GROUP INCADD1,723,1162,157,195+25.2%$47.9M
DIMENSIONAL FUND ADVISORS LPDOUBLED951,5891,946,479+104.6%$43.2M
MARSHALL WACE, LLPDOUBLED83,1471,488,917+1690.7%$33.1M
CITADEL ADVISORS LLCDOUBLED201,1441,143,958+468.7%$25.4M
Fiera Capital CorpTRIM1,380,620789,989-42.8%$17.5M
RAYMOND JAMES FINANCIAL INCADD451,644576,350+27.6%$12.8M
MILLENNIUM MANAGEMENT LLCDOUBLED158,548431,850+172.4%$9.6M
Nuveen, LLCTRIM718,333386,787-46.2%$8.6M
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
7 insiders, 50 transactions. Net -$113.8M — $0.00 bought, $113.8M sold.
DateInsiderTitleTypeSharesPriceValue
Sep 8, 2026Cox JohnCEO & PresidentSELL5,658$18.88$106.8K
Sep 8, 2026Kerr DouglasChief Medical OfficerSELL1,290$18.88$24.4K
Sep 8, 2026Friedl-Naderer JohannaChief Commercial OfficerSELL185$18.88$3.5K
Sep 4, 2026Kerr DouglasChief Medical OfficerSELL3,745$24.35$91.2K
Sep 4, 2026Friedl-Naderer JohannaChief Commercial OfficerSELL900$24.35$21.9K
Aug 14, 2026Rhodes Jason PDirectorSELL1,359,674$25.00$34.0M
Aug 14, 2026Rhodes Jason PDirectorSELL478,377$25.00$12.0M
Aug 14, 2026Rhodes Jason PDirectorSELL322,465$25.00$8.1M
Aug 13, 2026Cox JohnCEO & PresidentSELL4,986$26.28$131.0K
Aug 13, 2026Rhodes Jason PDirectorSELL94,415$26.20$2.5M
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for DYN.
Shares short
23,381,047
Settlement Sep 15, 2026
Change vs prior
+12.5%
Semi-monthly cycle
Days to cover
5.5
At avg daily volume
Of shares outstanding
≈12.5%
Estimate — not % of float
All DYN filing & press-release reports (44)